I agree, Hoskuld, that the MAA isn't a slam dunk, and I certainly believe that 3-71 for Schizophrenia is way far from that. I just wanted to point out that 3-71 has features beyond the PANSS scores racked up by Karuna that could well color the relative attractiveness of 3-71. One of the problems with Schizophrenia patients, as I understand it, is the adherence to regular dosing. Lesser side effects and improved cognition could tip the balance if the PANSS scores were relatively comparable to the SOC.
Market Data 
Markets 
AI
